CEO Watchlist: Week In Review (4/5/26)

TOP NEWS AFFECTING THE STOCK MARKET THIS WEEK:

Bullish on Orbit: Why Last Week's Moon Launch Is Signaling a Major Rally for These 5 Space Stocks! (Source)

Stocks mentioned: $RKLB, $LUNR, $ASTS, $PL, $IRDM

On Wednesday, April 1, 2026, the world watched as the Artemis 2 mission cleared the tower at Kennedy Space Center, carrying 4 astronauts toward the Moon for the first time in over 50 years. We are moving from an era of curious exploration to an era of space dominance, data, and global security. This isn't just a nostalgic "flags and footprints" moment, it is the definitive signal that the "Space Economy" has shifted from science fiction to a profitable reality...and those paying attention will be able to make a lot of money on this once in a lifetime shift.

The center of gravity for this movement is undeniably SpaceX. As the company prepares for its highly anticipated 2026 IPO (initial public offering), it is targeting a staggering $2 trillion valuation! To put that in perspective, SpaceX is currently generating an estimated $16 billion to $20 billion in annual revenue, meaning the market is pricing it at a 100x multiple! For those that don't know any better, this just means it's going to be VERY VERY expensive! This "SpaceX Premium" isn't based on today's cash flow; it’s a bet on their total vertical integration. SpaceX doesn't just build rockets; they own the "railroad" (Falcon and Starship) and the "telegraph lines" (Starlink). While some skeptics argue that a $2 trillion price tag is untethered from reality given the capital-intensive nature of hardware, proponents point to the fact that SpaceX has effectively commoditized access to orbit, making them the gatekeeper to a multi-trillion dollar frontier.

If SpaceX is truly the "gatekeeper" for a multi-trillion dollar market, then it isn't a far stretch that money will trickle down quite heavily into the sector as a whole. This is why the massive valuation for SpaceX creates a profound "valuation gap" for the rest of the sector. If the market is willing to pay $2 trillion for a dominant private player, then the handful of publicly traded space companies, currently valued between $3-$40 billion, look like massive mispricings. We are seeing a "rising tide" effect where the SpaceX IPO will likely force institutional desks to find public proxies to gain exposure to the sector. While SpaceX owns the launch, these other players own the critical niches of data, connectivity, and lunar logistics that make the space economy functional. Here are the top 5 space stocks we believe will directly benefit from this multi-trillion dollar structural shift:

Rocket Lab (RKLB): The most credible challenger to the SpaceX launch monopoly. They provide end-to-end mission services, from small-satellite launches to building the actual satellite buses for customers. Sitting at just $38 billion, we believe this is a name that could double from here.
Intuitive Machines (LUNR): The "LHT" (Lunar Heritage Technology) leader. This company is essentially the logistics provider for the Moon, having secured massive NASA contracts to provide the landers and data nodes necessary for the Artemis program. LUNR is currently sitting at just a $3.8 billion market cap. If it gets even close to Rocket Lab's size, let alone SpaceX, we are talking about a 10x from here. This is one of the higher-risk stocks in our opinion, and would definitely be cautious around this name, but it does offer massive upside potential if they execute.
AST SpaceMobile (ASTS): Building the first space-based cellular broadband network to connect directly to standard smartphones. Think of them as a global, space-based telecom carrier. Something a lot of people don't realize is that Google has a stock portoflio, and what's even more shocking to most people is that 25% of it is all-in on ASTS! So Google clearly has high conviction in the space economy as well.
Planet Labs (PL): A data company disguised as a satellite company. They capture a daily "scan" of the entire Earth, selling high-frequency imagery and AI-driven analytics to governments and agricultural giants. If you thought it was shocking that Google put 25% of their stock portfolio in ASTS, you'll really be shocked to find out that another 25% of their portfolio is in Planet Labs alone! That means 50% of their stock portfolio is in just these 2 space stocks.
Iridium (IRDM): The established veteran of LEO (Low Earth Orbit) communications, providing resilient, global voice and data services through a mature constellation that is already a proven "cash cow." This small $3 billion company is one of the least expensive names, premium-wise. It also hasn't ran-up as much as all the other space names, so we consider this one a bit of a hidden gem.

We aren't just betting on rockets; we are betting on the "Lunar Industrial Revolution." The Artemis 2 launch and the impending SpaceX IPO are going to go down as the beginning of the modern day "Space Race". With SpaceX setting a $2 trillion benchmark, the public markets are currently offering "distressed" prices for the very companies building the infrastructure of the 21st century. The window to buy the "railroads of the stars" at double-digit billion-dollar valuations is closing fast. Could there be volatility? Absolutely! This is a very high-risk sector of the market, but for investors like ourselves, who are looking to make massively outsized returns to the average hedge fund, we need to be taking bets where we have the highest conviction, even if it is high risk.

The nice thing is we are not the only investors looking into space as a massive investable opportunity. As we mentioned above, Google has 50% of their stock portfolio in 2 of the space stocks we mentioned. If a multi-trillion dollar company like Google is willing to put half of their investable stock portfolio into these space stocks, why wouldn't any investor at least consider making them part of their portfolio? Space is no longer a luxury for the few; it is the essential infrastructure of the future, and for the high-conviction investor (as well as Google), the mission has just begun!

Stock Spotlight: Tempus AI (Source)

Stocks mentioned: $TEM

Healthcare has been struggling for some time, especially when it comes to being able to consistently and accurately produce results for patients. In addition, patient records are deeply fragmented across different hospital systems, data is rarely connected, and doctors are routinely forced to make critical, life-or-death decisions without having the full picture. Tempus AI solves this systemic failure by operating as a highly advanced "medical data engine," cleaning up this chaotic information and running it through artificial intelligence to find clinical patterns that human eyes simply miss. Think of it as a navigation app for physicians: just as building Google Maps today would be completely impossible without billions of historical GPS data points, Tempus provides data-backed "directions" for the best personalized treatments, especially in complex cancer care. By standardizing this vital clinical and genomic information, Tempus drastically reduces human error and injects critical efficiency into healthcare when every second counts.

In the rapidly evolving world of artificial intelligence, an algorithm is only as good as the information feeding it, making data the ultimate competitive moat. Tempus has spent years quietly amassing one of the largest libraries of clinical and genomic data in the world, building an impenetrable fortress that competitors cannot easily replicate. Guided by a seasoned founding team with a proven track record of scaling billion-dollar tech ventures, Tempus is perfectly positioned at the explosive intersection of genomics and AI. Their long-term vision is staggering: they aim to build the "iOS of hospitals." If successful, Tempus will evolve into an indispensable, daily operating system where patient data is perfectly structured, AI models run in real-time, and doctors receive instant, personalized recommendations. Recognizing that medicine is rapidly moving away from a "one size fits all" approach and toward highly personalized, data-driven treatment, we believe it's only a matter of time until the market appreciates a name like this.

This ambitious operational dominance translates into a highly lucrative, multi-layered revenue model that effectively reduces overall investment risk. Tempus generates immediate cash flow by charging hospitals and insurers for essential genomic tests, but the true high-margin growth engine lies in its software and pharmaceutical partnerships. Hospitals pay recurring subscription fees for access to the AI platform, treating it like a premium clinical data service, while major drug companies eagerly purchase access to Tempus’s rich dataset to accelerate clinical trials and study how populations respond to specific medications. Early believers in this model are looking at a scenario akin to investing in Nvidia before the broader AI hardware boom. If Tempus successfully becomes the core infrastructure for AI-driven healthcare, the financial upside of global expansion and absolute dominance in cancer diagnostics is substantial.

However, no explosive growth story is without its shadows, and the bear case demands careful, objective consideration. Healthcare is notoriously slow to adopt new technologies, and Tempus faces fierce competition from established genomic players like Guardant Health and Exact Sciences. Furthermore, building massive data ecosystems and scaling advanced labs requires a massive cash burn, meaning immediate profitability remains elusive, and any sudden shifts in medical privacy regulations or insurance reimbursement policies could severely impact revenue. It also doesn't help that software stocks have been under attack lately in the market, which is why we see Tempus down over 50% from its all time high. But, for investors like ourselves who have been watching this stock like a hawk, this tends to be where opportunities lie. With it trading at basically its IPO price a couple years ago, we think now is the time for us to nibble at the name, and dollar cost average if it continues to move down. Tempus’ comprehensive hardware, software, and testing ecosystem gives it a distinct holistic advantage that will likely surge exponentially when the broader tech sector inevitably reaccelerates, and that's what we're betting on.

Ultimately, Tempus AI represents a high-conviction, asymmetrical opportunity for investors that are willing to look past the short-term volatility. It is highly risky and not a fit for conservative portfolios seeking safe, immediate cash-flowing businesses today. Instead, this asset is tailor-made for those who firmly believe AI will fundamentally rewrite the rules of medicine and who want concentrated exposure to both precision genomics and artificial intelligence in a single company. Tempus is actively building one of the most powerful medical data platforms in the world, and if they execute their massive vision, they will become the undisputed backbone of modern healthcare. By offering crucial diversification into the historically lagging healthcare sector while strictly adhering to a futuristic tech thesis, Tempus stands out as a compelling, must-watch asset for the future of medicine.

"Super Investor" Spotlight: David Tepper (Source)

Stocks mentioned: $BABA, $JD, $BIDU, $KWEB, $EWY, $GOOGL, $AMZN, $MU, $META, $TSM, $NVDA, $WHR, $NRG, $MSFT

This week’s "Super Investor" Spotlight features the legendary David Tepper, the founder of Appaloosa Management. For those unfamiliar with the term, a "Super Investor" is a elite fund manager who has demonstrated a unique ability to read market cycles and deliver massive returns over several decades. Tepper is widely considered one of the greatest hedge fund managers of all time, known for his bold style of investing where he makes massive, concentrated bets when he smells blood in the water.

But before we look at the specifics of his stock portfolio, it's important to note that when looking at a "Super Investor's" portfolio, we want to first make sure they are worthy of looking at. There are many people that manage millions or billions of dollars, but we are looking for the handful that consistently beats the overall market. That's why the first thing we do is pull up their portfolio performance vs. the S&P 500. Needless to say, Tepper is an absolute legend, and has basically doubled the S&P 500's performance over the past 3 years, as can be seen down below:

As you'll see above, Tepper's fund Appaloosa gained over 150% returns in the past 3 years, which is a massive outperformance not only to the S&P 500, but a majority of other "Super Investors". This is why every quarter, we look at his 13F filing to see where he is putting his $6.85 billion to work!

In Tepper’s latest update, it reveals a "Super Investor" who is playing a very specific and aggressive hand: reducing exposure to China while increasing exposure to U.S. and Korean technology stocks. Tepper heavily sold off many of his China-exposed tech names, such as Alibaba (BABA), JD.com (JD), Bidu (BIDU), and even a Chinese-tech ETF called KWEB. Instead, he rotated that money into some very large tech names, such as Google (GOOG) and Meta (META), and even some smaller but very strong momentum stocks such as Micron (MU), playing on the high memory demand we see currently. What was really interesting was that he didn't get rid of international exposure to Asia completely, but rather, rotated from China into Korea by investing into the iShares South Korea ETF (EWY). Of his 38 stock portfolio, here is his current top 10 holdings:

Alibaba Group (BABA) – 11.0%
Alphabet Inc (GOOGL) – 8.2%
Amazon.com Inc (AMZN) – 7.3%
Micron Technology (MU) – 6.2%
Meta Platforms (META) – 5.8%
Taiwan Semiconductor (TSM) – 5.0%
Nvidia Corp (NVDA) – 4.6%
Whirlpool Corp (WHR) – 4.1%
NRG Energy (NRG) – 3.8%
Microsoft Corp (MSFT) – 3.5%

David Tepper’s performance remains a benchmark for the industry. While the S&P 500 has seen a strong run over the last 3 years, Tepper’s tactical shifts, such as his rotation into key tech names, have allowed him to maintain his status as a top 1% "Super Investor." He proves that to achieve extraordinary returns, you often have to be able to rotate into the right names before the rest of the market realizes their potential, such as he did with Micron and EWY before their recent run-ups. We will continue to track Tepper’s moves closely, and update all of you on any important changes we find.

INSIDER STOCK TRADES FROM THE WEEK:

1. LuLuLemon (LULU) - Andre Maestrini (CEO) bought roughly $500,000 worth of LULU at an average price of $151.02/share on April 1, 2026, but it wasn't reported to the public until April 3, 2026. This is the second major insider buy on LULU within the past 2 weeks. (Source)

2. Rubrik (RBRK) - Mark McLaughlin (Director) bought roughly $500,000 of RBRK at an average price of $47.21/share on Mar. 30, 2026, but it wasn't reported to the public until April 1, 2026. (Source)

3. Epsilon Energy (EPSN) - Jason Stabell (CEO) bought roughly $125,000 of EPSN at an average price of $6.21/share between Mar. 27-30, 2026, and it was most recently reported to the public on March 31, 2026. (Source)

Over 2,000 people have already signed up for my FREE Masterclass video on how to unlock my exact strategies for finding winning stock/options trades! I'll share everything including how to find what Politicians and CEOs are buying. Don’t miss your chance to get in for FREE before spots fill up!